These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 16319509)
1. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. Souglakos J; Pallis A; Kakolyris S; Mavroudis D; Androulakis N; Kouroussis C; Agelaki S; Xenidis N; Milaki G; Georgoulias V Oncology; 2005; 69(5):384-90. PubMed ID: 16319509 [TBL] [Abstract][Full Text] [Related]
2. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial. Souglakos J; Vardakis N; Androulakis N; Kakolyris S; Kourousis C; Mavroudis D; Pallis A; Agelaki S; Kalbakis K; Georgoulias V Dig Dis; 2007; 25(1):100-5. PubMed ID: 17384515 [TBL] [Abstract][Full Text] [Related]
3. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. Souglakos J; Mavroudis D; Kakolyris S; Kourousis Ch; Vardakis N; Androulakis N; Agelaki S; Kalbakis K; Tsetis D; Athanasiadis N; Samonis G; Georgoulias V J Clin Oncol; 2002 Jun; 20(11):2651-7. PubMed ID: 12039926 [TBL] [Abstract][Full Text] [Related]
4. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer. Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628 [TBL] [Abstract][Full Text] [Related]
5. Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer. Fujishima H; Kikuchi I; Miyanaga O; Ueda A; Baba E; Mitsugi K; Harada M; Nakano S Int J Clin Oncol; 2004 Apr; 9(2):92-7. PubMed ID: 15108040 [TBL] [Abstract][Full Text] [Related]
6. Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study. Vamvakas L; Kakolyris S; Kouroussis C; Kandilis K; Mavroudis D; Ziras N; Androulakis N; Kalbakis K; Sarra E; Souglakos J; Georgoulias V; Am J Clin Oncol; 2002 Feb; 25(1):65-70. PubMed ID: 11823700 [TBL] [Abstract][Full Text] [Related]
7. Multicenter phase II study of CPT-11 fractionated over two days with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer. Recchia F; Nuzzo A; Lalli A; Di Lullo L; De Filippis S; Saggio G; Di Blasio A; Rea S Anticancer Res; 2003; 23(3C):2903-8. PubMed ID: 12926132 [TBL] [Abstract][Full Text] [Related]
8. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study. Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920 [TBL] [Abstract][Full Text] [Related]
9. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer. Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L Oncology; 2004; 66(5):371-8. PubMed ID: 15331924 [TBL] [Abstract][Full Text] [Related]
10. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495 [TBL] [Abstract][Full Text] [Related]
11. Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients. Sasaki Y; Hamaguchi T; Arai T; Goto A; Ura T; Muro K; Yamada Y; Shirao K; Shimada Y Anticancer Res; 2014 Apr; 34(4):2029-34. PubMed ID: 24692743 [TBL] [Abstract][Full Text] [Related]
12. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. Falcone A; Ricci S; Brunetti I; Pfanner E; Allegrini G; Barbara C; Crinò L; Benedetti G; Evangelista W; Fanchini L; Cortesi E; Picone V; Vitello S; Chiara S; Granetto C; Porcile G; Fioretto L; Orlandini C; Andreuccetti M; Masi G; J Clin Oncol; 2007 May; 25(13):1670-6. PubMed ID: 17470860 [TBL] [Abstract][Full Text] [Related]
13. Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. Aranda E; Valladares M; Martinez-Villacampa M; Benavides M; Gomez A; Massutti B; Marcuello E; Constenla M; Cámara JC; Carrato A; Dueñas R; Reboredo M; Navarro M; Díaz-Rubio E Ann Oncol; 2009 Feb; 20(2):251-7. PubMed ID: 18718892 [TBL] [Abstract][Full Text] [Related]
14. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231 [TBL] [Abstract][Full Text] [Related]
15. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer. Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809 [TBL] [Abstract][Full Text] [Related]
16. FOLFIRI chemotherapy for metastatic colorectal cancer patients. Kamnerdsupaphon P; Lorvidhaya V; Chitapanarux I; Tonusin A; Sukthomya V J Med Assoc Thai; 2007 Oct; 90(10):2121-7. PubMed ID: 18041432 [TBL] [Abstract][Full Text] [Related]
17. [Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer]. Li J; Xu JM; Li J; Zhang XD; Bai Y; Chu YP; Wang YH; Liu DQ; Jin ML; Shen L Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):225-7. PubMed ID: 18756942 [TBL] [Abstract][Full Text] [Related]
18. A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer. Reina JJ; Aparicio J; Salvador J; Pica JM; Rueda A; Lorenzo A; de la Puente CG; Borrega P; Moreno-Nogueira JA Cancer Chemother Pharmacol; 2003 Oct; 52(4):339-45. PubMed ID: 12851783 [TBL] [Abstract][Full Text] [Related]
19. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study. Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041 [TBL] [Abstract][Full Text] [Related]
20. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. Fuchs CS; Marshall J; Mitchell E; Wierzbicki R; Ganju V; Jeffery M; Schulz J; Richards D; Soufi-Mahjoubi R; Wang B; Barrueco J J Clin Oncol; 2007 Oct; 25(30):4779-86. PubMed ID: 17947725 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]